^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

dactinomycin

i
Other names: Act D, GNF-PF-2290, NCI-C04682, NSC-3053
Company:
Generic mfg.
Drug class:
Topoisomerase II inhibitor, RNA synthesis inhibitor
Related drugs:
6d
DDX3X promotes ILF3 stability to accelerate neuroblastoma progression via M2 macrophage polarization. (PubMed, Brain Res)
Actinomycin D treatment combined with RT-qPCR was used to assess ILF3 mRNA stability...In vivo, DDX3X inhibitor, RK-33, markedly inhibited NB tumor growth and metastasis and enhanced M1 macrophage polarization, which was partially reversed by ILF3 overexpression. DDX3X promotes NB progression by stabilizing ILF3 mRNA, thereby facilitating M2 macrophage polarization.
Journal
|
DDX3X (DEAD-Box Helicase 3 X-Linked) • IL3 (Interleukin 3)
|
dactinomycin
7d
A novel positive-feedback loop between CEBPA and NAT10 promotes non-small cell lung cancer progression. (PubMed, Cytotechnology)
Additionally, mRNA stability was evaluated using actinomycin D assay...NAT10 catalyzed ac4C acetylation on CEBPA mRNA, enhancing its stability and increasing CEBPA protein expression, thereby promoting the malignant progression of NSCLC. The identification of this feedback loop provides a preclinical rationale for developing NSCLC therapeutic strategies targeting NAT10 or CEBPA.
Journal
|
CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
dactinomycin
7d
The role of CSTF2 in gastric cancer: implications for therapy. (PubMed, Eur J Med Res)
CSTF2 promotes gastric cancer progression by post-transcriptionally stabilizing TGM2 mRNA, and its overexpression is closely related to poor prognosis. The elucidated CSTF2-TGM2 regulatory axis may offer a promising and innovative therapeutic target for gastric carcinoma treatment.
Journal
|
TGM2 (Transglutaminase 2)
|
dactinomycin
8d
Evolutionary Therapy for Rhabdomyosarcoma (clinicaltrials.gov)
P2, N=12, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=28 --> 12
Enrollment closed • Enrollment change
|
FOXO1 (Forkhead box O1)
|
doxorubicin hydrochloride • cyclophosphamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin • Navelbine oral (vinorelbine tartrate oral)
10d
Wilms Tumor 1-associated Protein Promotes Sepsis-induced Disseminated Intravascular Coagulation by Stabilizing Intercellular Adhesion Molecule 1 Via N6-methyladenosine Modification. (PubMed, Cardiovasc Drugs Ther)
WTAP stabilizes ICAM1 mRNA via m6A modification, thereby increasing ICAM1 expression and enhancing TF activity in LPS-stimulated HUVECs. Knocking down WTAP in rats improves sepsis-induced DIC.
Journal
|
WT1 (WT1 Transcription Factor) • ICAM1 (Intercellular adhesion molecule 1) • WTAP (WT1 Associated Protein)
|
dactinomycin
16d
CircPSMA4 as a novel circular RNA enhances the proliferation migration invasion and metabolism of bladder cancer cells through the miR-767-3p/HIF1A pathway. (PubMed, Sci Rep)
The expression and in vitro functionality of circPSMA4 in T24 bladder cancer cell lines were analyzed using RNase R treatment, actinomycin D stability assay, nucleocytoplasmic separation, real-time quantitative PCR, Western blot, dual-luciferase reporter assay, cellular energy metabolism analysis, scratch assay, Transwell migration and invasion assay, CCK-8 proliferation assay, lactate and glucose uptake detection, and ATP production measurement...CircPSMA4 functions as a miR-767-3p sponge, regulating miR-767-3p to influence the expression of HIF1A, thereby promoting the proliferation, migration, invasion, and metabolic activities of bladder cancer cells, as well as tumor formation. CircPSMA4 facilitates the proliferation, migration, invasion, and metabolism of bladder cancer cells through the miR-767-3p/HIF1A pathway.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
dactinomycin
20d
Mechanism of METTL14-mediated RAD21 mRNA epigenetic transcriptome modification in inhibiting thyroid cancer development. (PubMed, World J Surg Oncol)
METTL14 inhibits tumorigenesis in TC mice in vivo by mediating m6A modification of RAD21 and decreasing RAD21 mRNA stability.
Journal
|
RAD21 (RAD21 Cohesin Complex Component) • METTL14 (Methyltransferase 14)
|
dactinomycin
21d
CircCGNL1 Suppresses Nasopharyngeal Carcinoma Progression by Targeting IGF2BP3 and Inhibiting AKT/mTOR Signaling. (PubMed, J Biochem Mol Toxicol)
The circular nature, subcellular localization, and stability of circCGNL1 were validated through RNase R digestion, actinomycin D treatment, and FISH assay...This study identifies circCGNL1 as a tumor-suppressive circRNA that inhibits NPC progression by binding to IGF2BP3 and suppressing the AKT/mTOR signaling. These findings reveal a novel regulatory mechanism in NPC and highlight circCGNL1 as a promising biomarker and therapeutic target.
Journal
|
IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
dactinomycin
22d
hsa_circ_0001776 regulates the progression of acute myeloid leukemia through the miR-1269b/PTEN axis. (PubMed, Turk J Biol)
Its circular nature and stability were confirmed via actinomycin D treatment and RNase R digestion...hsa_circ_0001776 suppresses AML progression via the miR-1269b/PTEN axis. These findings suggest that hsa_circ_0001776 may serve as a potential diagnostic biomarker and therapeutic target for AML.
Journal
|
MIR1269A (MicroRNA 1269a)
|
dactinomycin
22d
Mechanism of methyltransferase METTL14 mediating m6A modification and regulating SIRT5 expression to promote ferroptosis and repress gastric cancer progression. (PubMed, Eur J Med Res)
METTL14 stabilizes SIRT5 mRNA via m6A modification, upregulating SIRT5 expression and inducing ferroptosis, thereby inhibiting GC progression.
Journal
|
GPX4 (Glutathione Peroxidase 4) • METTL14 (Methyltransferase 14) • SIRT5 (Sirtuin 5)
|
dactinomycin
24d
ARST1431: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (clinicaltrials.gov)
P3, N=325, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
Trial completion date
|
cyclophosphamide • irinotecan • Torisel (temsirolimus) • vincristine • vinorelbine tartrate • dactinomycin
28d
Orbital Rhabdomyosarcoma in a Pediatric Patient With Costello Syndrome. (PubMed, Ophthalmic Plast Reconstr Surg)
Treatment with chemotherapy consisted of vincristine, dactinomycin, and cyclophosphamide, and received 8 cycles of photon beam radiation. Radiological surveillance up to 12 months showed no signs of recurrence or metastatic lesions. Patients with CS are at a high risk of developing rhabdomyosarcoma and clinicians should be vigilant in the context of any clinical orbital signs of disease.
Journal
|
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation
|
cyclophosphamide • vincristine • dactinomycin